Coming soon!

Background

Diagnosis, prognosis, and treatment of leukodystrophies

van der Knaap MS, Schiffmann R, Mochel F, Wolf NI. Diagnosis, prognosis, and treatment of leukodystrophies. Lancet Neurol. 2019 Oct;18(10):962-972. doi: 10.1016/S1474-4422(19)30143-7. Epub 2019 Jul 12. PMID: 31307818.

Safety and efficacy of guanabenz in early-childhood onset vanishing white matter: primary analysis of a single-arm, phase 1/2 trial

van der Knaap MS, Verbeek RJ, van Voorst RJ, Gonzato E, Stellingwerff MD, Voermans MMC, Postema MC, Dekker H, van den Berg E, Steenweg ME, Bet PM, Bartelink IH, Teunissen CE, Abbink TEM, Berkhof J, van Eekelen R, Wolf NI. Safety and efficacy of guanabenz in early-childhood onset vanishing white matter: primary analysis of a single-arm, phase 1/2 trial. Lancet Neurol. 2026 Sep;25(9):818-829. doi: 10.1016/S1474-4422(26)00241-3. PMID: 42586097.

From preclinical animal studies to clinical trials

Metovic J, Li Y, Gong Y, Eichler F. Gene therapy for the leukodystrophies: From preclinical animal studies to clinical trials. Neurotherapeutics. 2024 Jul;21(4):e00443. doi: 10.1016/j.neurot.2024.e00443. Epub 2024 Sep 13. PMID: 39276676; PMCID: PMC11418141.

Megalencephalic leukoencephalopathy with subcortical cysts: a variant update and review of the literature

Passchier EMJ, Bisseling Q, Helman G, van Spaendonk RML, Simons C, Olsthoorn RCL, van der Veen H, Abbink TEM, van der Knaap MS, Min R. Megalencephalic leukoencephalopathy with subcortical cysts: a variant update and review of the literature. Front Genet. 2024 Feb 29;15:1352947. doi: 10.3389/fgene.2024.1352947. PMID: 38487253; PMCID: PMC10938252.

GPCR drug discovery: new agents, targets and indications

Lorente JS, Sokolov AV, Ferguson G, Schiöth HB, Hauser AS, Gloriam DE. GPCR drug discovery: new agents, targets and indications. Nat Rev Drug Discov. 2025 Jun;24(6):458-479. doi: 10.1038/s41573-025-01139-y. Epub 2025 Mar 3. PMID: 40033110.